Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a pioneer of digitizing scent, proudly announces its revolutionary AI Nose for robotics application and invites robotics companies worldwide to join Ainos Alliance. This technology aims to equip robots with the ability to "smell," filling a long-standing gap in sensory capabilities. Powered by advanced artificial intelligence (AI) and micro-electromechanical systems (MEMS) gas sensors, AI Nose redefines how robots interact with the world, enabling transformative applications across industrial, healthcare, and everyday environments.
Ainos is now inviting robotics and humanoid companies worldwide to join its Ainos Alliance, leveraging nearly a decade of research, development, and success in this field. With multiple patents secured, AI Nose represents the culmination of years of innovation and is poised to lead the next wave of advancements in robotics. This is the perfect time to collaborate and integrate this groundbreaking technology into next-generation robots.
AI Nose is a Game-Changer, Elevating Robot's Interaction with Our World
1. Transforming Home Safety
Detects gas leaks, burning odors, and other safety hazards, sending immediate alerts to prevent accidents.
Enhances smart home environments by proactively addressing unpleasant odors, such as those from kitchen waste.
2. Revolutionizing Healthcare
Enables non-invasive early detection of diseases by analyzing volatile organic compounds (VOCs) emitted by you.
Provides real-time health monitoring for chronic disease patients, offering smarter healthcare solutions.
3. Enhancing Industrial and Environmental Safety
Detects hazardous gas leaks with precision, improving workplace safety and driving smart manufacturing.
Supports environmental protection efforts by monitoring air pollutants in real-time, providing actionable data for policy-making.
The Perfect Time to Act: A Thriving Robotics Market
1. Explosive Growth in Robotics
The global robotics market is projected to grow from $100.59 billion in 2025 to $178.63 billion by 2030, with a compound annual growth rate (CAGR) of 12.17%.
(Source: Mordor Intelligence)
2. Increasing Demand for Industrial Robots
In 2023, 541,302 industrial robots were installed globally, the second highest installation in history, with 70% deployed in Asia. These numbers reflect the critical role robotics plays in manufacturing, safety, and environmental solutions.
(Source: International Federation of Robotics)
3. Humanoid Robots on the Rise
The humanoid robot market is expected to expand from $2.9 billion in 2024 to $46.31 billion by 2031, with a CAGR of 48.6%. The convergence of AI and robotics makes now the ideal moment for companies to enter this burgeoning market.
(Source: Coherent Market Insights)
4. The Growing Need for Smell Technology
The electronic nose market is projected to grow from $26.04 billion in 2024 to $65.79 billion by 2031, with a CAGR of 14.2%. This underscores the importance of olfactory sensing in robotics and beyond.
(Source: Coherent Market Insights)
Join the Ainos Alliance Now
Ainos' AI Nose technology harnesses nearly 10 years of dedicated research and development. Securing multiple patents along the way, the company has established itself as a pioneer in olfactory sensing technology. By joining the Ainos Alliance, robotics and humanoid companies can gain access to this disruptive and patented technology, ensuring a competitive edge in a rapidly growing market.
Key Benefits of Joining the Ainos Alliance:
Leverage Decades of Expertise: Collaborate with a proven leader in AI and sensory technology.
Secure First-Mover Advantage: Integrate AI Nose Technology into your products to capture market share.
Expand Applications: Unlock new possibilities in industrial safety, healthcare, and smart living.
Shape the Future Together: Collaborate on groundbreaking innovations that redefine the capabilities of robots.
"Originated from healthcare use-case, our AI Nose technology represents nearly a decade of innovation and perseverance," said Chun-Hsien (Eddy) Tsai, CEO of Ainos. "With the robotics and humanoid markets experiencing unprecedented growth, this is the moment to act. Partnering with us now means joining a team with a proven track record of success and ensuring your company's position at the forefront of the industry."
To join the Ainos Alliance or learn more about AI Nose, contact us today:
Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name "Ainos" combines "AI" and "Nose" to signify our commitment to enabling AI with the ability to smell and individuals to live healthier. Our clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. Follow Ainos on X, formerly known as Twitter, (@AinosInc), LinkedIn, and Webull Corporate Connect to stay up-to-date.
Safe Harbor Statement
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements can be identified by the use of words such as "anticipate," "believe," "estimate," "approximate," "expect," "intend," "plan," "predict," "project," "target," "future," "likely," "strategy," "foresee," "may," "guidance," "potential," "outlook," "forecast," "should," "will" or other similar words or phrases. Similarly, statements that describe the Company's objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements are based only on the Company's current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. The Company's actual results may differ materially from those indicated in the forward-looking statements.
Important factors that could cause the Company's actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release include, among others, the cost of production and sales potential of the products announced in this press release; the Company's dependence on projected revenues from the sale of current or future products; the Company's limited cash and history of losses; the Company's ability to achieve profitability; the Company's ability to raise additional capital to continue the Company's product development; the ability to accurately predict the future operating results of the Company; the ability to advance Ainos' current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates the Company develops; the ability to obtain and maintain regulatory approval of Ainos' product candidates; delays in completing the development and commercialization of the Company's current and future product candidates, which could result in increased costs to the Company, delay or limit the ability to generate revenue and adversely affect the business, financial condition, results of operations and prospects of the Company; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the accuracy of third-party market research data, the impact of competitive or alternative products, technologies and pricing; disruption in research and development facilities; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; potential cybersecurity attacks; increased requirements and costs related to cybersecurity; the Company's ability to realize the benefits of third party licensing agreements; the Company's ability to obtain and maintain intellectual property protection for Ainos product candidates; compliance with applicable laws, regulations and tariffs; continued listing on and compliance with the applicable regulations of the Nasdaq Capital Market; and the Company's success in managing growth. A more complete description of these risk factors and others is included in the "Risk Factors" section of Ainos' Annual Report on Form 10-K for the year ended December 31, 2023, and other public filings with the U.S. Securities and Exchange Commission ("SEC"), many of which risks are beyond the Company's control. In addition to the risks described above and in the Company's filings with the SEC, other unknown or unpredictable factors also could cause actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release.
The forward-looking statements made in this press release are expressly qualified in their entirety by the foregoing cautionary statements. Any forward-looking statements contained in this press release represent Ainos' views only as of today and should not be relied upon as representing its views as of any subsequent date. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly update or revise any forward-looking statement to reflect changed assumptions, the occurrence of anticipated or unanticipated events or changes to the future results over time or otherwise, except as required by law.
